I'll work through all 45 articles, applying independent judgment against the triage metadata. For efficiency, I group by triage score tier and note key adjustments from Phase 1 scores.

---

Triage Score 9 Articles

Article 1 — Habib et al. — Targeted Therapy in Pancreatic Ductal Adenocarcinoma

PMID: 42645357 | 🔴 EARLY_CANCER_DETECTION

Phase 2 Assessment: The triage metadata labels this "Randomized study," but the plain_summary and title strongly indicate this is a narrative/systematic review that references the phase III RASolute 302 trial as one piece of evidence. The study_design classification appears to be a pipeline misclassification. The key finding about daraxonrasib improving OS in RAS-mutant metastatic PDAC is clinically significant and references real trial data, but this article itself does not report original trial results.

Dimension	Score	Rationale
Scientific Novelty	7	RAS inhibition in PDAC is genuinely novel territory; daraxonrasib (multiselective RAS inhibitor) is a recent class. Review synthesizes a rapidly moving landscape.
Clinical Relevance	8	PDAC survival is dismal (~12% 5-yr); any RAS-targeted improvement is highly meaningful clinically
Population Reach	7	~60,000 PDAC diagnoses/year in US; globally ~500,000; RAS mutations in ~90%
Implementation Speed	4	RASolute 302 is phase III, but FDA approval pathway and access timelines suggest 2–4 years to broad adoption
Evidence Strength	5	This is a review article (abstract only); underlying RCT data is strong, but this article itself is secondary synthesis

Key quantitative result: RASolute 302 trial: daraxonrasib superior to chemotherapy in RAS-mutant metastatic PDAC (effect size not extractable from abstract) External validation: Phase III RCT (RASolute 302) referenced — underlying evidence is strong Main limitation: Review article only; abstract-level access; no original data; full treatment landscape nuance inaccessible Equity implications: PDAC disproportionately affects older adults and Black Americans; targeted therapy access may worsen disparities if cost is prohibitive Evidence Maturity (revised): Exploratory → Validated (for RAS inhibition concept; review-level synthesis)

Phase 2 Composite Score: (8×0.30) + (7×0.25) + (7×0.20) + (4×0.15) + (5×0.10) = 2.40 + 1.75 + 1.40 + 0.60 + 0.50 = 6.65

---

Triage Score 8 Articles

Article 2 — Emara et al. — IVUS-guided vs. angiography-guided PCI in left main disease

PMID: 42648372 | ⚪ PROMISING_PRELIMINARY

Note: This article is matched to "Hematologic malignancies" by the pipeline — a clear topic mismatch. This is a cardiovascular/interventional cardiology meta-analysis. The triage score of 8 appears inflated given the topic mismatch and non-significant primary endpoint.

Dimension	Score	Rationale
Scientific Novelty	4	IVUS guidance in PCI is an established concept; this is an updated meta-analysis of 4 RCTs
Clinical Relevance	7	Left main coronary disease is high-stakes; PCI guidance technique directly affects outcomes
Population Reach	7	Left main coronary disease is common in the elderly with CAD; globally millions of PCI procedures annually
Implementation Speed	7	IVUS is already in clinical use; results (non-significant MACE difference) inform but do not dramatically change practice
Evidence Strength	7	Meta-analysis of 4 RCTs, n=1,446; robust design, though null result (RR 0.57, 95% CI 0.30–1.09, p=0.09) leaves clinical uncertainty

Key quantitative result: MACE RR 0.57 (95% CI 0.30–1.09; p=0.09) — non-significant trend favoring IVUS External validation: Meta-analysis of 4 RCTs — pooled evidence; individual trial heterogeneity unclear Main limitation: Only 4 RCTs, likely underpowered for MACE; borderline p-value suggests trend may become significant with more data; abstract only Equity implications: IVUS adds procedural cost and expertise requirements; may disadvantage lower-resource settings and hospitals without advanced catheterization lab infrastructure Evidence Maturity (revised): Exploratory → Exploratory (null result, insufficient power to definitively change practice)

Phase 2 Composite Score: (7×0.30) + (7×0.25) + (4×0.20) + (7×0.15) + (7×0.10) = 2.10 + 1.75 + 0.80 + 1.05 + 0.70 = 6.40

---

Article 3 — Tarhini et al. — Genetic susceptibility to ICI-related dermatitis in melanoma

PMID: 42647409 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	6	Polygenic risk scores for irAEs are a developing field; two-SNP PRS for ICI dermatitis is novel in melanoma specifically
Clinical Relevance	6	Dermatitis is common with ICIs; predicting severity could inform monitoring/prophylaxis but AUC 0.63 limits clinical utility
Population Reach	6	~100,000 melanoma patients/year in US receive ICIs; broader ICI populations across other cancers
Implementation Speed	3	AUC 0.63 is too modest for clinical implementation; needs validation cohort and replication
Evidence Strength	5	Cohort, n=744, prospective derivation but no independent replication; modest discrimination (AUC 0.63)

Key quantitative result: Two-SNP PRS AUC 0.63 for dermatitis risk — modest discrimination External validation: None reported; single-cohort derivation Main limitation: No external validation; AUC 0.63 likely too low for clinical actionability; abstract only Equity implications: GWAS-derived SNPs historically perform worse in non-European populations; PRS may underserve minority melanoma patients Evidence Maturity (revised): Exploratory (confirmed)

Phase 2 Composite Score: (6×0.30) + (6×0.25) + (6×0.20) + (3×0.15) + (5×0.10) = 1.80 + 1.50 + 1.20 + 0.45 + 0.50 = 5.45

---

Triage Score 7 Articles

Article 4 — Vasiliadis et al. — Meniscal centralization vs. isolated repair meta-analysis

PMID: 42646642 | 🟢 NEAR_TERM_IMPLEMENTABLE

Note: Matched to "Hematologic malignancies" — clear pipeline mismatch. Orthopedic sports medicine article.

Dimension	Score	Rationale
Scientific Novelty	4	Clarifying additive benefit of centralization is an incremental surgical question
Clinical Relevance	5	Directly informs surgical decision-making for meniscus surgery
Population Reach	5	Medial meniscus tears are common (~1M procedures/year in US); this affects a subset needing root repair
Implementation Speed	7	Results are immediately applicable: adding centralization offers no benefit, simplifying surgery
Evidence Strength	5	Systematic review of 1 RCT + 5 retrospective cohort studies, n=309; high heterogeneity (I²=89%); modest follow-up (mean 11.2 months)

Key quantitative result: MME reduction MD 0.4 mm (95% CI −0.34 to 1.22; p=0.27; I²=89%) — non-significant Main limitation: High heterogeneity (I²=89%); single RCT; short mean follow-up; abstract only Equity implications: Surgical access disparities broadly apply; simpler procedure (no centralization) may reduce OR time and cost, potentially improving access Evidence Maturity: Exploratory (high heterogeneity prevents definitive conclusion)

Phase 2 Composite Score: (5×0.30) + (5×0.25) + (4×0.20) + (7×0.15) + (5×0.10) = 1.50 + 1.25 + 0.80 + 1.05 + 0.50 = 5.10

---

Article 5 — Kresevic et al. — VLM for liver steatosis on ultrasound

PMID: 42648026 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	7	Adapting a vision-language foundation model for hepatic steatosis grading on multi-image ultrasound is technically novel
Clinical Relevance	6	MASLD affects ~25% of adults globally; automated grading could reduce inter-observer variability and specialist burden
Population Reach	9	MASLD is among the most prevalent chronic liver diseases worldwide; enormous potential reach
Implementation Speed	4	95.1% accuracy is impressive, but validation across diverse hardware, patient populations, and institutions required before deployment
Evidence Strength	5	Retrospective cohort, n=1,925 (substantial for AI); no external validation; abstract only; single-center implied

Key quantitative result: Feature-level VLM accuracy 95.1% (κ=0.90–0.96) — strong performance on internal validation Main limitation: No external validation reported; retrospective single-institution design; abstract only Equity implications: If deployed broadly, AI-assisted ultrasound grading could democratize MASLD assessment in low-resource settings without specialist hepatologists Evidence Maturity: Exploratory (confirmed)

Phase 2 Composite Score: (6×0.30) + (9×0.25) + (7×0.20) + (4×0.15) + (5×0.10) = 1.80 + 2.25 + 1.40 + 0.60 + 0.50 = 6.55

---

Article 6 — Kasper et al. — Systemic immune state and myeloid remodeling in neoadjuvant PD-L1 blockade

PMID: 42648751 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	7	Identifying pre-treatment NK-T cell frequency and exhausted T-cell signatures as predictors of pathological response in HNSCC neoadjuvant IO is genuinely informative
Clinical Relevance	6	Could guide patient selection for neoadjuvant atezolizumab in HNSCC, a disease with significant unmet need
Population Reach	4	HNSCC affects ~65,000/year in US; neoadjuvant IO is still investigational; small n=20 limits generalizability
Implementation Speed	2	n=20 is far too small; needs prospective validation before any clinical implementation
Evidence Strength	4	n=20; no control arm for biomarker analysis; "randomized" label likely refers to the parent trial design, not the biomarker analysis; abstract only

Key quantitative result: NK-T cell frequency and exhausted T-cell expansion associated with robust pathological regression — no HR/AUC reported in abstract External validation: None Main limitation: Very small n=20; exploratory biomarker analysis; no quantitative thresholds provided; abstract only Equity implications: Biomarker-guided selection raises access equity concerns if tests are expensive or not widely available Evidence Maturity: Exploratory (confirmed)

Phase 2 Composite Score: (6×0.30) + (4×0.25) + (7×0.20) + (2×0.15) + (4×0.10) = 1.80 + 1.00 + 1.40 + 0.30 + 0.40 = 4.90

---

Article 7 — Raja & Kandagari — GLP-1 Receptor Agonists and Obesity-Related Cancers

PMID: 42645635 | ⚪ PROMISING_PRELIMINARY

Note: This appears to be a narrative review, not a randomized study as classified.

Dimension	Score	Rationale
Scientific Novelty	5	GLP-1/cancer connection is an active and growing literature; this review synthesizes it but does not add original data
Clinical Relevance	7	GLP-1 RAs are being prescribed to hundreds of millions; cancer risk reduction would be a major secondary benefit
Population Reach	9	Obesity affects 1+ billion globally; 13 obesity-related malignancies; enormous potential public health impact
Implementation Speed	3	Review explicitly notes residual confounding, surveillance bias, insufficient follow-up — practice change not yet warranted
Evidence Strength	4	Narrative/systematic review (abstract only); underlying studies have significant methodological limitations as noted

Key quantitative result: Not extractable from abstract; review notes findings are vulnerable to confounding Main limitation: Underlying observational studies subject to residual confounding, surveillance bias, comparator selection bias; no RCT data on cancer endpoints Equity implications: GLP-1 access is severely limited by cost/coverage in lower-income populations and globally; cancer prevention benefit would compound existing disparities if access inequitable Evidence Maturity: Exploratory (confirmed)

Phase 2 Composite Score: (7×0.30) + (9×0.25) + (5×0.20) + (3×0.15) + (4×0.10) = 2.10 + 2.25 + 1.00 + 0.45 + 0.40 = 6.20

---

Article 8 — Chien et al. — EDL-FET biosensor for p-Tau217 and Aβ in blood

PMID: 42648826 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	7	Multiplexed EDL-FET biosensor detecting p-Tau217 and Aβ42/40 simultaneously in whole blood is technically novel; point-of-care Alzheimer's biomarker detection is a high-priority space
Clinical Relevance	7	p-Tau217 is the leading blood-based Alzheimer's biomarker; simultaneous multiplexed detection in whole blood (not plasma only) extends access
Population Reach	9	55+ million people with dementia globally; Alzheimer's diagnosis is a massive unmet need
Implementation Speed	3	Device requires validation against CSF/PET gold standards in larger cohorts; regulatory pathway ahead
Evidence Strength	4	Cohort, sample size not reported; "unknown" species suggests device validation study design; abstract only; no diagnostic accuracy metrics beyond p-tau217 differentiation statement

Key quantitative result: p-Tau217 strongest differentiation of cognitive status in plasma; whole blood performance also demonstrated Main limitation: Sample size not reported; no head-to-head comparison with approved blood tests (e.g., Lumipulse); species/population unclear; abstract only Equity implications: Point-of-care blood-based test could radically democratize Alzheimer's screening beyond specialized memory clinics, especially in LMICs and rural settings Evidence Maturity: Exploratory (confirmed)

Phase 2 Composite Score: (7×0.30) + (9×0.25) + (7×0.20) + (3×0.15) + (4×0.10) = 2.10 + 2.25 + 1.40 + 0.45 + 0.40 = 6.60

---

Article 9 — Wong et al. — Phase 2 mRNA COVID-19 vaccine trial

PMID: 42647564 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	Next-generation mRNA COVID vaccines are an active iterative space; not groundbreaking but informative
Clinical Relevance	6	Non-inferior immune responses with acceptable safety profile supports vaccine pipeline
Population Reach	9	COVID vaccination is a global public health priority; billions eligible
Implementation Speed	5	Phase 2 complete; Phase 3 and regulatory approval required; 2–3 year pathway
Evidence Strength	6	Phase 2 RCT, n=425, active-controlled, observer-blind; reasonable design quality

Key quantitative result: All but lowest dose of CV0701 induced immune responses comparable to approved vaccine; no related serious adverse events, no deaths External validation: Active-controlled comparison provides relative benchmark Main limitation: Phase 2 only; immunogenicity endpoints only (no efficacy against infection); abstract only Equity implications: New vaccine candidates in pipeline support dose optimization and potential improved access formats; equity in rollout remains a global challenge Evidence Maturity: Exploratory (confirmed)

Phase 2 Composite Score: (6×0.30) + (9×0.25) + (4×0.20) + (5×0.15) + (6×0.10) = 1.80 + 2.25 + 0.80 + 0.75 + 0.60 = 6.20

---

Triage Score 6 Articles (Selected Key Analyses)

Article 10 — Moon & Jeon — Malignant small-bowel tumors epidemiology in Asia

PMID: 42648700

Dimension	Score	Rationale
Scientific Novelty	3	Epidemiological trend analysis; attribution to improved detection is a known phenomenon
Clinical Relevance	4	Contextual awareness; no direct practice change
Population Reach	5	Asian populations + global GI oncology community
Implementation Speed	5	Awareness/guideline informing; no direct intervention
Evidence Strength	4	Cohort/registry study; sample size not reported; abstract only

Phase 2 Composite Score: (4×0.30) + (5×0.25) + (3×0.20) + (5×0.15) + (4×0.10) = 1.20 + 1.25 + 0.60 + 0.75 + 0.40 = 4.20

---

Article 11 — Vodicka et al. — DLBCL third-line survival improvement, Czech Republic

PMID: 42647866 | 🟠 NOVEL_TREATMENT

Dimension	Score	Rationale
Scientific Novelty	5	Real-world confirmation of era-based survival improvement in r/r DLBCL; valuable but confirmatory
Clinical Relevance	7	43% vs 29% two-year OS (HR=0.70) is a meaningful real-world survival gain; validates newer treatment regimens
Population Reach	6	DLBCL is the most common aggressive lymphoma; ~25,000 new US cases/year; global burden substantial
Implementation Speed	6	Newer agents (polatuzumab, loncastuximab, bispecifics) are already approved; real-world data validates existing practice
Evidence Strength	5	Retrospective cohort, n=134 (modest); two-era comparison; subject to selection bias and treatment heterogeneity; abstract only

Key quantitative result: HR=0.70 (p=0.01); 2-year OS 43% vs 29% Main limitation: Small n=134; retrospective; treatment heterogeneity across era; Czech Republic-specific healthcare context Equity implications: Access to CAR-T and bispecific antibodies is highly uneven globally; survival gains concentrated in well-resourced centers Evidence Maturity: Exploratory (confirmed; real-world data supporting but not proving causation)

Phase 2 Composite Score: (7×0.30) + (6×0.25) + (5×0.20) + (6×0.15) + (5×0.10) = 2.10 + 1.50 + 1.00 + 0.90 + 0.50 = 6.00

---

Article 12 — Schulz et al. — MDS IB1/IB2 vs AML-MR therapy initiation

PMID: 42645532 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	2022 ICC reclassification of MDS→AML at 10% blasts is recent; real-world impact data is needed
Clinical Relevance	6	Time-to-treatment differences across reclassified entities directly informs clinical urgency and pathway design
Population Reach	5	MDS/AML-MR collectively affect ~50,000/year in US
Implementation Speed	6	Classification already in use; data informs implementation urgency
Evidence Strength	5	Observational registry, n=928 (strong for this disease); single-center (Düsseldorf); medium confidence classification

Phase 2 Composite Score: (6×0.30) + (5×0.25) + (5×0.20) + (6×0.15) + (5×0.10) = 1.80 + 1.25 + 1.00 + 0.90 + 0.50 = 5.45

---

Article 13 — Chen et al. — GSTP1 functional landscape in cancer

PMID: 42648416 | 🔴 EARLY_CANCER_DETECTION

Dimension	Score	Rationale
Scientific Novelty	5	GSTP1 beyond detoxification is a genuine conceptual expansion; review synthesis
Clinical Relevance	4	No direct clinical application yet; foundational science framing
Population Reach	5	Broad cancer relevance; GSTP1 silencing is pan-cancer
Implementation Speed	2	Purely exploratory/mechanistic review
Evidence Strength	3	Review article; no original data; abstract only

Phase 2 Composite Score: (4×0.30) + (5×0.25) + (5×0.20) + (2×0.15) + (3×0.10) = 1.20 + 1.25 + 1.00 + 0.30 + 0.30 = 4.05

---

Article 14 — Herzog et al. — PD Effluentome multi-omics atlas

PMID: 42646630 | 🔴 EARLY_CANCER_DETECTION

Dimension	Score	Rationale
Scientific Novelty	7	First comprehensive multi-omics atlas of PD effluent (207 metabolites, 2,970 proteins) is a significant reference dataset
Clinical Relevance	4	Currently foundational; biomarker discovery tool for peritoneal dialysis monitoring, not yet clinical application
Population Reach	4	~300,000 peritoneal dialysis patients globally; niche but high-unmet-need population
Implementation Speed	3	Atlas creation; clinical application requires further development
Evidence Strength	5	n=207 (samples, not patients implied); multi-omics methodology; solid design for discovery work; abstract only

Phase 2 Composite Score: (4×0.30) + (4×0.25) + (7×0.20) + (3×0.15) + (5×0.10) = 1.20 + 1.00 + 1.40 + 0.45 + 0.50 = 4.55

---

Article 15 — Chen et al. — MicroRNAs in kidney cancer (urine/blood)

PMID: 42645213 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	miRNA biomarkers in RCC is an established field; review with modest n=26 studies
Clinical Relevance	5	Noninvasive RCC detection is an unmet need; urinary miRNAs have practical advantages
Population Reach	6	~80,000 kidney cancer diagnoses/year in US
Implementation Speed	3	Small review; no standardized assay platform yet
Evidence Strength	3	Review of 26 studies; observational; medium confidence; abstract only

Phase 2 Composite Score: (5×0.30) + (6×0.25) + (4×0.20) + (3×0.15) + (3×0.10) = 1.50 + 1.50 + 0.80 + 0.45 + 0.30 = 4.55

---

Article 16 — Hayes et al. — PPAR-regulated pathways in cholestatic liver diseases

PMID: 42645170 | 🔴 EARLY_CANCER_DETECTION

Dimension	Score	Rationale
Scientific Novelty	5	Liquid biopsy EVs for PPAR pathway identification in PBC/PSC is conceptually novel
Clinical Relevance	4	PBC/PSC have limited therapeutic options; highly relevant to a small population
Population Reach	3	PBC/PSC are rare (prevalence ~50–200/million)
Implementation Speed	2	Conceptual review; no clinical application yet
Evidence Strength	3	Observational/review; unknown species; abstract only; medium confidence

Phase 2 Composite Score: (4×0.30) + (3×0.25) + (5×0.20) + (2×0.15) + (3×0.10) = 1.20 + 0.75 + 1.00 + 0.30 + 0.30 = 3.55

---

Article 17 — Wang et al. — 7T MRI for glioma IDH/WHO grade

PMID: 42649122 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	6	7T MRI vascular feature extraction for glioma molecular subtyping is technically innovative
Clinical Relevance	6	Preoperative non-invasive glioma grading/IDH status could reduce surgical risk or guide approach
Population Reach	5	~25,000 glioma diagnoses/year in US
Implementation Speed	3	7T MRI availability is extremely limited globally; significant infrastructure barrier
Evidence Strength	5	Retrospective, n=218; AUC 0.816–0.843 (IDH), 0.834–0.874 (WHO grade); internal validation only

Phase 2 Composite Score: (6×0.30) + (5×0.25) + (6×0.20) + (3×0.15) + (5×0.10) = 1.80 + 1.25 + 1.20 + 0.45 + 0.50 = 5.20

---

Article 18 — Zeng et al. — MRI radiomics for breast cancer neoadjuvant chemo response

PMID: 42648921 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	MRI radiomics + clinical model for NAC response in breast cancer is an active but crowded field
Clinical Relevance	7	Predicting pCR with AUC 0.859 (externally validated at 0.862) is clinically meaningful for treatment de-escalation decisions
Population Reach	8	Breast cancer is the most common cancer in women globally; NAC is standard in locally advanced disease
Implementation Speed	4	Retrospective; needs prospective validation and integration into clinical workflow
Evidence Strength	6	n=373, internal + external validation (rare for radiomics studies); AUC 0.862 external = strong performance

Key quantitative result: AUC 0.859 internal, 0.862 external validation — notably consistent, suggesting low overfitting Main limitation: Retrospective; abstract only; center-specific MRI protocols may not generalize Equity implications: MRI access disparities affect low-resource settings; AI-assisted reading could help but hardware remains a barrier Evidence Maturity: Exploratory → borderline Validated (external validation achieved)

Phase 2 Composite Score: (7×0.30) + (8×0.25) + (5×0.20) + (4×0.15) + (6×0.10) = 2.10 + 2.00 + 1.00 + 0.60 + 0.60 = 6.30

---

Article 19 — Young et al. — Body composition and colon cancer recurrence

PMID: 42648596 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	4	Body composition as a prognostic factor in CRC is well-established; this adds data
Clinical Relevance	5	Could inform surveillance intensity for stage II–III colon cancer
Population Reach	7	Colorectal cancer is 3rd most common cancer globally; stage II–III is large subset
Implementation Speed	5	CT-based body composition analysis is feasible now if validated
Evidence Strength	5	Retrospective cohort, n=615; 120 recurrences; needs prospective validation per authors

Phase 2 Composite Score: (5×0.30) + (7×0.25) + (4×0.20) + (5×0.15) + (5×0.10) = 1.50 + 1.75 + 0.80 + 0.75 + 0.50 = 5.30

---

Article 20 — Kim et al. — OXTR methylation and brain connectivity in panic disorder

PMID: 42648552 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Linking OXTR DNAm to structural connectome in panic disorder is novel
Clinical Relevance	4	Mechanistic; no direct clinical application
Population Reach	6	Panic disorder affects 2–3% of population globally
Implementation Speed	2	Epigenetic biomarkers for psychiatric conditions remain far from clinical use
Evidence Strength	5	n=563 PD + 210 HC; observational; medium confidence; abstract only

Phase 2 Composite Score: (4×0.30) + (6×0.25) + (5×0.20) + (2×0.15) + (5×0.10) = 1.20 + 1.50 + 1.00 + 0.30 + 0.50 = 4.50

---

Article 21 — Tobin — Precision oncology in breast cancer review

PMID: 42647673 | 🔴 EARLY_CANCER_DETECTION

Dimension	Score	Rationale
Scientific Novelty	3	Overview/educational review of established precision oncology advances in breast cancer
Clinical Relevance	6	High practical relevance for APPs and primary oncology providers managing breast cancer
Population Reach	8	Breast cancer is extremely common; audience of APPs is large
Implementation Speed	7	Knowledge synthesis; immediately educationally applicable
Evidence Strength	3	Observational review; no original data; single author; abstract only; medium confidence

Phase 2 Composite Score: (6×0.30) + (8×0.25) + (3×0.20) + (7×0.15) + (3×0.10) = 1.80 + 2.00 + 0.60 + 1.05 + 0.30 = 5.75

---

Article 22 — Yang et al. — Acylations in malignancies review

PMID: 42648417 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Acylation modifications (beyond acetylation) in cancer is a novel epigenetic area
Clinical Relevance	3	Mechanistic review; no clinical application yet
Population Reach	5	Pan-cancer relevance
Implementation Speed	2	Purely foundational
Evidence Strength	3	Review; abstract only; medium confidence

Phase 2 Composite Score: (3×0.30) + (5×0.25) + (5×0.20) + (2×0.15) + (3×0.10) = 0.90 + 1.25 + 1.00 + 0.30 + 0.30 = 3.75

---

Article 23 — Kajiura et al. — Oncology specialist availability and TTF in lung cancer

PMID: 42645367 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Linking workforce data with genomic registry outcomes is methodologically novel
Clinical Relevance	5	Workforce distribution affects TTF in lung cancer — important health systems finding
Population Reach	7	Lung cancer is the leading cause of cancer death globally; nationwide Japan registry n=5,456
Implementation Speed	4	Policy-level change required; slower to implement
Evidence Strength	5	Large registry cohort n=5,456; observational; single-country context (Japan)

Phase 2 Composite Score: (5×0.30) + (7×0.25) + (5×0.20) + (4×0.15) + (5×0.10) = 1.50 + 1.75 + 1.00 + 0.60 + 0.50 = 5.35

---

Article 24 — Yu et al. — GLP-1/semaglutide in hypothalamic obesity RCT review

PMID: 42644866 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Hypothalamic obesity is a rare and underserved condition; semaglutide data here is novel for this population
Clinical Relevance	6	Hypothalamic obesity (post-craniopharyngioma etc.) has very limited treatment options
Population Reach	3	Hypothalamic obesity is rare (relative to general obesity)
Implementation Speed	4	Semaglutide is available but not approved for this indication
Evidence Strength	5	Systematic review of RCTs; sample size not reported; abstract only

Phase 2 Composite Score: (6×0.30) + (3×0.25) + (5×0.20) + (4×0.15) + (5×0.10) = 1.80 + 0.75 + 1.00 + 0.60 + 0.50 = 4.65

---

Article 25 — Chen et al. — Expert perspectives on obesity management

PMID: 42644855 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	3	Expert consensus; not primary research
Clinical Relevance	6	Implementation-focused; addresses real-world barriers for a high-burden disease
Population Reach	9	Obesity affects 1+ billion globally
Implementation Speed	6	Expert consensus is immediately actionable for policy/practice
Evidence Strength	3	Expert opinion; observational; abstract only; medium confidence

Phase 2 Composite Score: (6×0.30) + (9×0.25) + (3×0.20) + (6×0.15) + (3×0.10) = 1.80 + 2.25 + 0.60 + 0.90 + 0.30 = 5.85

---

Article 26 — Deeksha et al. — AGEs and PTSD

PMID: 42645661 | 🟠 NOVEL_TREATMENT

Dimension	Score	Rationale
Scientific Novelty	6	Linking AGE accumulation to PTSD neuropsychiatric pathology is a novel mechanistic framing
Clinical Relevance	4	Mechanistic review; no clinical interventions validated yet
Population Reach	7	PTSD affects ~7–8% of population lifetime; significant unmet need
Implementation Speed	2	Dietary/pharmacological AGE interventions are speculative at this stage
Evidence Strength	3	Review; observational; medium confidence; abstract only

Phase 2 Composite Score: (4×0.30) + (7×0.25) + (6×0.20) + (2×0.15) + (3×0.10) = 1.20 + 1.75 + 1.20 + 0.30 + 0.30 = 4.75

---

Article 27 — Yang et al. — Cognitive concordance in older married couples

PMID: 42646836 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	5	Domain-specific cognitive concordance in spousal pairs is a novel angle on shared-environment aging
Clinical Relevance	4	Basic science of aging cognition; limited direct clinical application
Population Reach	7	Aging cognition is globally relevant; n=1,566
Implementation Speed	3	Observational; policy/screening implications unclear
Evidence Strength	5	n=1,566 married couples; observational; abstract only; medium confidence; JAMA Network Open is high-quality venue

Phase 2 Composite Score: (4×0.30) + (7×0.25) + (5×0.20) + (3×0.15) + (5×0.10) = 1.20 + 1.75 + 1.00 + 0.45 + 0.50 = 4.90

---

Article 28 — Kuwabara et al. — CIDP clinical practice review

PMID: 42649076 | 🟡 UNDERSERVED_POPULATION

Dimension	Score	Rationale
Scientific Novelty	3	National survey data; not primary research on treatment
Clinical Relevance	5	Comprehensive CIDP state-of-the-field; relevant to neurologists managing this rare disease
Population Reach	4	CIDP is rare (~5/100,000); relative to this population the unmet need is high
Implementation Speed	4	Guideline-informing; near-term for practice standardization
Evidence Strength	4	n=330 (national survey scope); observational; medium confidence

Phase 2 Composite Score: (5×0.30) + (4×0.25) + (3×0.20) + (4×0.15) + (4×0.10) = 1.50 + 1.00 + 0.60 + 0.60 + 0.40 = 4.10

---

Article 29 — Tallman et al. — Equity in genome sequencing, UK 100K Genomes Project

PMID: 42648159 | 🟡 UNDERSERVED_POPULATION

Dimension	Score	Rationale
Scientific Novelty	6	Quantifying ancestry-related variant prioritization disparities in a national clinical genome sequencing program is novel and actionable
Clinical Relevance	7	IRR 2.77 for East African vs European variant prioritization reveals systematic diagnostic inequity with direct clinical consequences
Population Reach	6	Rare disease patients + broader implications for all clinical genome sequencing programs globally
Implementation Speed	5	Findings are immediately actionable for bioinformatics pipeline recalibration
Evidence Strength	6	Large national cohort (100K Genomes); n reported as 33 may be a metadata error (likely thousands); EBioMedicine peer-reviewed

Key quantitative result: East African ancestry: IRR 2.77 (95% CI 2.33–3.29) more variants for clinical review vs European — indicates major workload and interpretability disparity Main limitation: Sample size metadata appears erroneous (n=33 listed but 100K Genomes implies far larger); abstract only Equity implications: This IS an equity study — directly highlights how non-European patients receive systematically different genomic workups, risking under-diagnosis or over-investigation Evidence Maturity: Exploratory → Validated (large national dataset, clear quantitative disparity)

Phase 2 Composite Score: (7×0.30) + (6×0.25) + (6×0.20) + (5×0.15) + (6×0.10) = 2.10 + 1.50 + 1.20 + 0.75 + 0.60 = 6.15

---

Article 30 — Sclafani et al. — Imaging cardiac amyloidosis

PMID: 42645872 | 🟡 UNDERSERVED_POPULATION

Dimension	Score	Rationale
Scientific Novelty	4	ATTR/AL amyloidosis imaging is an active, evolving field; review level
Clinical Relevance	7	Cardiac amyloidosis is treatable now (tafamidis); early imaging-based detection is practice-changing
Population Reach	5	CA is underdiagnosed; true prevalence likely ~1% of HFpEF patients = large absolute numbers
Implementation Speed	6	Imaging modalities (nuclear, MRI, echo) are currently available; workflow integration feasible
Evidence Strength	4	Observational review; sample size not reported; medium confidence

Phase 2 Composite Score: (7×0.30) + (5×0.25) + (4×0.20) + (6×0.15) + (4×0.10) = 2.10 + 1.25 + 0.80 + 0.90 + 0.40 = 5.45

---

Triage Score 5 Articles (Rapid Assessment)

Article 31 — David et al. — Testosterone deficiency consensus

PMID: 42647144 | ⚪ PROMISING_PRELIMINARY

• Scores: Novelty 3, Relevance 5, Reach 6, Speed 7, Evidence 4
• Composite: (5×0.30)+(6×0.25)+(3×0.20)+(7×0.15)+(4×0.10) = 1.50+1.50+0.60+1.05+0.40 = 5.05

Article 32 — Park et al. — Automated sepsis pathogen detection

PMID: 42648850 | ⚪ PROMISING_PRELIMINARY

• Scores: Novelty 6, Relevance 6, Reach 7, Speed 4, Evidence 4
• Composite: (6×0.30)+(7×0.25)+(6×0.20)+(4×0.15)+(4×0.10) = 1.80+1.75+1.20+0.60+0.40 = 5.75

Article 33 — Byrne et al. — Oral mycosis fungoides case report

PMID: 42648786 | ⚪ PROMISING_PRELIMINARY

• Scores: Novelty 3, Relevance 3, Reach 2, Speed 3, Evidence 2
• Composite: (3×0.30)+(2×0.25)+(3×0.20)+(3×0.15)+(2×0.10) = 0.90+0.50+0.60+0.45+0.20 = 2.65

Article 34 — Diaz et al. — YOLOv11 leukemia cell detection

PMID: 42645391 | ⚪ PROMISING_PRELIMINARY

• Scores: Novelty 5, Relevance 5, Reach 6, Speed 5, Evidence 4
• Composite: (5×0.30)+(6×0.25)+(5×0.20)+(5×0.15)+(4×0.10) = 1.50+1.50+1.00+0.75+0.40 = 5.15

Article 35 — Gamage et al. — RNA biosensors in oncology review

PMID: 42648526 | 🔴 EARLY_CANCER_DETECTION

• Scores: Novelty 5, Relevance 4, Reach 7, Speed 2, Evidence 3
• Composite: (4×0.30)+(7×0.25)+(5×0.20)+(2×0.15)+(3×0.10) = 1.20+1.75+1.00+0.30+0.30 = 4.55

Article 36 — Sun et al. — Intratumoral heterogeneity imaging for bone metastasis in breast cancer

PMID: 42648923 | ⚪ PROMISING_PRELIMINARY

• Scores: Novelty 5, Relevance 6, Reach 8, Speed 3, Evidence 4
• Composite: (6×0.30)+(8×0.25)+(5×0.20)+(3×0.15)+(4×0.10) = 1.80+2.00+1.00+0.45+0.40 = 5.65

Article 37 — Ding et al. — PARP inhibitors and tumor microenvironment review

PMID: 42648415 | ⚪ PROMISING_PRELIMINARY

• Scores: Novelty 5, Relevance 5, Reach 6, Speed 2, Evidence 3
• Composite: (5×0.30)+(6×0.25)+(5×0.20)+(2×0.15)+(3×0.10) = 1.50+1.50+1.00+0.30+0.30 = 4.60

Article 38 — Tang & Liu — SPARC/CD276 and ICI resistance in liver cancer

PMID: 42647088 | ⚪ PROMISING_PRELIMINARY

• Non-human (in vitro); Clinical Relevance capped at 4
• Scores: Novelty 6, Relevance 4, Reach 5, Speed 2, Evidence 3
• Composite: (4×0.30)+(5×0.25)+(6×0.20)+(2×0.15)+(3×0.10) = 1.20+1.25+1.20+0.30+0.30 = 4.25

Article 39 — Tymm et al. — Cardiac tertiary immune niches in ICI myocarditis

PMID: 42647623 | ⚪ PROMISING_PRELIMINARY

• Animal model; Clinical Relevance capped at 5
• Scores: Novelty 8, Relevance 5, Reach 6, Speed 2, Evidence 4
• Composite: (5×0.30)+(6×0.25)+(8×0.20)+(2×0.15)+(4×0.10) = 1.50+1.50+1.60+0.30+0.40 = 5.30

Article 40 — Shen & Heiland — UNITE® lysosomal vaccine for allergy

PMID: 42648983 | ⚪ PROMISING_PRELIMINARY

• Animal model; Clinical Relevance capped at 5
• Scores: Novelty 6, Relevance 5, Reach 7, Speed 2, Evidence 3
• Composite: (5×0.30)+(7×0.25)+(6×0.20)+(2×0.15)+(3×0.10) = 1.50+1.75+1.20+0.30+0.30 = 5.05

Article 41 — Ge et al. — Proteomic landscape of neuroendocrine carcinomas

PMID: 42648907 | ⚪ PROMISING_PRELIMINARY

• Scores: Novelty 8, Relevance 6, Reach 5, Speed 3, Evidence 5
• Composite: (6×0.30)+(5×0.25)+(8×0.20)+(3×0.15)+(5×0.10) = 1.80+1.25+1.60+0.45+0.50 = 5.60

Article 42 — Zhang et al. — IDE-mediated GLP-1 degradation and long-acting agonist design

PMID: 42647645 | ⚪ PROMISING_PRELIMINARY

• Scores: Novelty 7, Relevance 4, Reach 7, Speed 2, Evidence 4
• Composite: (4×0.30)+(7×0.25)+(7×0.20)+(2×0.15)+(4×0.10) = 1.20+1.75+1.40+0.30+0.40 = 5.05

Article 43 — Katragadda et al. — GLP-1s and nonscarring alopecia

PMID: 42647098 | ⚪ PROMISING_PRELIMINARY

• Scores: Novelty 5, Relevance 6, Reach 8, Speed 5, Evidence 5
• Composite: (6×0.30)+(8×0.25)+(5×0.20)+(5×0.15)+(5×0.10) = 1.80+2.00+1.00+0.75+0.50 = 6.05

Article 44 — Proshkina et al. — Valve-in-valve TAVR review

PMID: 42648863 | ⚪ PROMISING_PRELIMINARY

• Scores: Novelty 4, Relevance 6, Reach 6, Speed 5, Evidence 4
• Composite: (6×0.30)+(6×0.25)+(4×0.20)+(5×0.15)+(4×0.10) = 1.80+1.50+0.80+0.75+0.40 = 5.25

Article 45 — Taniguchi et al. — VCP R191Q astrocyte tau pathology

PMID: 42648719 | ⚪ PROMISING_PRELIMINARY

• Scores: Novelty 6, Relevance 3, Reach 2, Speed 2, Evidence 3
• Composite: (3×0.30)+(2×0.25)+(6×0.20)+(2×0.15)+(3×0.10) = 0.90+0.50+1.20+0.30+0.30 = 3.20

---

Conflict Summary

No direct head-to-head conflicts exist across articles (different disease areas/designs). Minor thematic tensions:

• GLP-1/cancer: Article 7 (review) acknowledges the GLP-1/cancer signal is real but methodologically fragile — consistent with general literature uncertainty
• AI diagnostics: Multiple radiomics/AI articles (Articles 5, 17, 18, 36) report high internal accuracy but lack external multi-site validation — a pattern-level concern for the field

---

Ranked Impact Table

Rank	Article	Flag	Impact Score	Phase 1 Triage Score	Clinical Relevance	Population Reach	Scientific Novelty	Implementation Speed	Evidence Strength	Study Design
1	Art. 1 — Habib et al. — PDAC Targeted Therapy Review	🔴	6.65	9	8	7	7	4	5	Review (with RCT data)
2	Art. 8 — Chien et al. — EDL-FET Alzheimer's biosensor	⚪	6.60	7	7	9	7	3	4	Cohort
3	Art. 5 — Kresevic et al. — VLM for liver steatosis	⚪	6.55	7	6	9	7	4	5	Cohort
4	Art. 2 — Emara et al. — IVUS vs. angio-guided PCI meta-analysis	⚪	6.40	8	7	7	4	7	7	Meta-analysis of RCTs
5	Art. 18 — Zeng et al. — MRI radiomics breast cancer NAC response	⚪	6.30	6	7	8	5	4	6	Retrospective cohort (ext. validated)
6	Art. 7 — Raja & Kandagari — GLP-1 and obesity-related cancers	⚪	6.20	7	7	9	5	3	4	Narrative review
7	Art. 9 — Wong et al. — Phase 2 mRNA COVID-19 vaccine	⚪	6.20	7	6	9	4	5	6	Phase 2 RCT
8	Art. 29 — Tallman et al. — Genomic sequencing equity	🟡	6.15	6	7	6	6	5	6	Cohort (national)
9	Art. 43 — Katragadda et al. — GLP-1s and alopecia	⚪	6.05	5	6	8	5	5	5	Propensity-matched cohort
10	Art. 11 — Vodicka et al. — DLBCL third-line survival improvement	🟠	6.00	6	7	6	5	6	5	Retrospective cohort
11	Art. 25 — Chen et al. — Expert perspectives on obesity management	⚪	5.85	6	6	9	3	6	3	Expert consensus
12	Art. 32 — Park et al. — Automated sepsis pathogen detection	⚪	5.75	6	6	7	6	4	4	Observational/technical
13	Art. 21 — Tobin — Precision oncology in breast cancer	🔴	5.75	6	6	8	3	7	3	Review
14	Art. 41 — Ge et al. — NEC proteomic landscape	⚪	5.60	5	6	5	8	3	5	Observational
15	Art. 36 — Sun et al. — ITH imaging for bone metastasis in breast cancer	⚪	5.65	5	6	8	5	3	4	Cohort
16	Art. 3 — Tarhini et al. — Genetic susceptibility ICI dermatitis	⚪	5.45	8	6	6	6	3	5	Cohort
17	Art. 12 — Schulz et al. — MDS/AML-MR therapy initiation	⚪	5.45	6	6	5	5	6	5	Registry observational
18	Art. 30 — Sclafani et al. — Imaging cardiac amyloidosis	🟡	5.45	6	7	5	4	6	4	Review
19	Art. 23 — Kajiura et al. — Oncologist availability and lung cancer TTF	⚪	5.35	6	5	7	5	4	5	Registry cohort
20	Art. 19 — Young et al. — Body composition and colon cancer recurrence	⚪	5.30	6	5	7	4	5	5	Retrospective cohort
21	Art. 39 — Tymm et al. — Cardiac tertiary immune niches in ICI myocarditis	⚪	5.30	5	5	6	8	2	4	Animal model
22	Art. 17 — Wang et al. — 7T MRI glioma grading	⚪	5.20	6	6	5	6	3	5	Retrospective
23	Art. 34 — Diaz et al. — YOLOv11 leukemia cell detection	⚪	5.15	5	5	6	5	5	4	Observational/AI
24	Art. 44 — Proshkina et al. — Valve-in-valve TAVR review	⚪	5.25	5	6	6	4	5	4	Review
25	Art. 4 — Vasiliadis et al. — Meniscal centralization meta-analysis	🟢	5.10	7	5	5	4	7	5	Systematic review/meta-analysis
26	Art. 31 — David et al. — Testosterone deficiency primary care consensus	⚪	5.05	6	5	6	3	7	4	Expert consensus
27	Art. 40 — Shen & Heiland — UNITE® allergy vaccine	⚪	5.05	5	5	7	6	2	3	Animal model
28	Art. 42 — Zhang et al. — IDE GLP-1 degradation	⚪	5.05	5	4	7	7	2	4	Observational/mechanistic
29	Art. 6 — Kasper et al. — Immune state and PD-L1 blockade in HNSCC	⚪	4.90	7	6	4	7	2	4	Randomized (n=20)
30	Art. 27 — Yang et al. — Cognitive concordance in older couples	⚪	4.90	6	4	7	5	3	5	Observational
31	Art. 26 — Deeksha et al. — AGEs and PTSD	🟠	4.75	6	4	7	6	2	3	Review
32	Art. 24 — Yu et al. — GLP-1 in hypothalamic obesity	⚪	4.65	6	6	3	5	4	5	Systematic review
33	Art. 37 — Ding et al. — PARP inhibitors and TME review	⚪	4.60	5	5	6	5	2	3	Review
34	Art. 14 — Herzog et al. — PD Effluentome atlas	🔴	4.55	6	4	4	7	3	5	Observational/omics
35	Art. 15 — Chen et al. — miRNA in kidney cancer	⚪	4.55	6	5	6	4	3	3	Review
36	Art. 35 — Gamage et al. — RNA biosensors in oncology	🔴	4.55	5	4	7	5	2	3	Review
37	Art. 20 — Kim et al. — OXTR methylation in panic disorder	⚪	4.50	6	4	6	5	2	5	Observational
38	Art. 38 — Tang & Liu — SPARC/CD276 in liver cancer	⚪	4.25	5	4	5	6	2	3	In vitro
39	Art. 10 — Moon & Jeon — Small-bowel tumor epidemiology Asia	⚪	4.20	6	4	5	3	5	4	Cohort/registry
40	Art. 13 — Chen et al. — GSTP1 functional landscape	🔴	4.05	6	4	5	5	2	3	Review
41	Art. 28 — Kuwabara et al. — CIDP clinical practice	🟡	4.10	6	5	4	3	4	4	Observational/survey
42	Art. 16 — Hayes et al. — PPAR pathways in cholestatic liver disease	🔴	3.55	6	4	3	5	2	3	Review
43	Art. 45 — Taniguchi et al. — VCP R191Q tau pathology	⚪	3.20	5	3	2	6	2	3	Case/observational
44	Art. 22 — Yang et al. — Acylations in malignancies	⚪	3.75	6	3	5	5	2	3	Review
45	Art. 33 — Byrne et al. — Oral mycosis fungoides case report	⚪	2.65	5	3	2	3	3	2	Case report

---

Rank Justification — Top 3

#1 — Article 1: Habib et al. — PDAC Targeted Therapy 🔴 Pancreatic ductal adenocarcinoma remains one of oncology's most formidable challenges, with fewer than 15% of patients surviving five years. This review captures a genuinely inflection-point moment: the RASolute 302 phase III trial data showing daraxonrasib — a multiselective RAS inhibitor — improving survival over chemotherapy in previously treated RAS-mutant metastatic PDAC. Since RAS mutations drive ~90% of PDAC cases, this is among the broadest-reaching precision oncology advances in this cancer type in years. Though the article is a review (not the original trial report), it synthesizes a rapidly evolving landscape with high confidence classification and achieves the highest weighted composite score on the strength of its clinical relevance and population reach dimensions.

Why it matters: For a disease that has seen minimal survival improvement in decades, a targeted RAS inhibitor showing phase III benefit could redefine the treatment algorithm for the majority of PDAC patients.

---

#2 — Article 8: Chien et al. — EDL-FET Biosensor for Alzheimer's Biomarkers ⚪ With 55+ million people living with dementia globally and Alzheimer's disease driving the majority of cases, the need for accessible, non-invasive, point-of-care diagnostic tools is enormous. This multiplexed biosensor simultaneously detects p-Tau217 and the Aβ42/40 ratio — the leading blood-based Alzheimer's biomarkers — from whole blood and plasma, including in stroke patients (a particularly vulnerable and diagnostically complex group). p-Tau217 differentiated cognitive status in both matrices, with strongest performance in plasma. The device-level innovation and the massive potential reach drive this high composite score despite early-stage evidence.

Why it matters: A point-of-care blood test for Alzheimer's biomarkers could bring early diagnosis out of specialized academic centers and into primary care and underserved communities worldwide.

---

#3 — Article 5: Kresevic et al. — VLM for Liver Steatosis on Ultrasound ⚪ MASLD affects roughly 1 in 4 adults globally and is the most common chronic liver disease worldwide — yet its grading typically requires specialized hepatologist review or liver biopsy. This vision-language foundation model achieved 95.1% accuracy (κ=0.90–0.96) on multi-image ultrasound, outperforming image-only baselines in a cohort of 1,925 patients. The combination of massive population reach, strong reported accuracy on internal validation, and the potential for AI-assisted ultrasound to work in settings without specialist hepatologists makes this a high-impact finding, though it requires external validation before deployment.

Why it matters: If validated externally, automated AI grading of fatty liver disease on routine ultrasound could democratize MASLD diagnosis and monitoring at global scale.

---

PHASE 4 — Deep Dives

---

[HOOK]

Pancreatic cancer kills nearly as many people as it diagnoses — roughly 90% of patients don't survive five years. For decades, that devastating statistic barely budged, not because oncologists weren't trying, but because pancreatic cancer had one of the most impenetrable molecular fortresses in all of oncology: the RAS oncogene. That fortress may be finally cracking.

---

[THE DISCOVERY]

A review published in Current Oncology synthesizes the current state of targeted therapy in pancreatic ductal adenocarcinoma — and at its center sits a striking finding from the RASolute 302 phase III clinical trial. A drug called daraxonrasib, a multiselective RAS inhibitor, outperformed standard chemotherapy in patients with previously treated metastatic pancreatic cancer harboring oncogenic RAS mutations. That's not a niche subgroup — RAS mutations drive approximately 90% of all pancreatic ductal adenocarcinomas. The molecular target is nearly universal in this disease.

Think of RAS as a stuck accelerator in a car: it keeps driving cancer cell growth even when it shouldn't. For decades, drug developers couldn't find a way to turn it off. Daraxonrasib represents a new generation of RAS inhibitors designed to target not just one form of mutant RAS, but multiple variants at once.

---

[THE SCIENCE BEHIND IT]

The RASolute 302 trial is a randomized phase III study comparing daraxonrasib directly to chemotherapy in RAS-mutant metastatic PDAC patients who had already received prior treatment — a notoriously difficult patient population where options are few and response rates low. Phase III is the gold standard: it's the trial level that regulatory agencies require for approval decisions. This review, written by a team at the University of Saskatchewan, contextualizes this result within the broader PDAC targeted therapy landscape, covering KRAS, TP53, CDKN2A, and SMAD4 as key drivers.

The main limitation here is that we're working from a review article, not the original trial publication — so precise effect sizes, overall survival curves, and safety profiles for RASolute 302 aren't fully available from this abstract. The underlying trial data will be critical to fully assess magnitude of benefit and toxicity.

---

[WHO THIS HELPS]

Patients with metastatic pancreatic ductal adenocarcinoma who have received at least one prior line of therapy and whose tumors carry oncogenic RAS mutations — which, again, is the vast majority of PDAC patients. In the United States alone, roughly 60,000 new PDAC diagnoses occur each year; globally, around half a million. The potential reach of an effective RAS-targeted therapy in this disease is extraordinary.

---

[THE REAL-WORLD IMPACT]

If daraxonrasib secures regulatory approval — a significant if, pending full trial data review — it could enter the PDAC treatment algorithm as a biomarker-selected second-line option. For oncologists currently cycling patients through increasingly futile chemotherapy regimens, a targeted agent with phase III survival benefit is a meaningful addition. For patients, it could mean more time and potentially better quality of life than chemotherapy. Cost and access will be critical: targeted therapies typically carry high price tags, and pancreatic cancer disproportionately affects older adults and Black Americans who already face systemic treatment access disparities.

---

[WHAT WE STILL DON'T KNOW]

The specific survival benefit — how many months, what the hazard ratio is, whether the advantage is durable or followed by rapid resistance — is not extractable from this review abstract. We also don't know the toxicity profile of daraxonrasib in this population, how it compares to the specific chemotherapy regimen used as the control arm, or whether all RAS mutation variants respond equally. RAS inhibition has historically been mutation-specific (KRAS G12C inhibitors work; G12D does not respond the same way), so understanding which RAS variants drive response to daraxonrasib will be essential.

---

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate — Phase III RCT is high-quality evidence; full data needed to confirm magnitude
• Translation Speed: 2–5 years to potential regulatory approval and access, depending on FDA/EMA review timelines and label specifics
• Barrier Analysis:
  • Regulatory: Phase III complete — regulatory submission likely underway or anticipated
  • Reimbursement: Targeted oncology drugs face aggressive payer scrutiny; PDAC patients often have limited life expectancy that complicates coverage negotiations
  • Cost: Likely high; could restrict access in lower-income countries and underinsured patients in the US
  • Infrastructure: RAS mutation testing will require standardized companion diagnostic deployment
  • Equity: Black Americans have higher PDAC incidence; equitable access to this drug will require deliberate effort

---

[CALL TO ACTION / CLOSING]

Pancreatic cancer's stranglehold on survival statistics isn't inevitable — and for the first time, a drug targeting the very mutation that drives most cases has cleared a phase III hurdle. Watch for the full RASolute 302 publication: the details there will tell us whether we're witnessing a genuine turning point in one of oncology's hardest fights.

---

---

[HOOK]

Left main coronary artery disease is one of the most dangerous conditions a cardiologist can encounter. The left main supplies blood to the majority of the heart's muscle — block it, and the consequences are catastrophic. Every decision in the catheterization lab matters. So when a new meta-analysis asks whether using ultrasound imaging inside the artery leads to better outcomes than traditional X-ray guidance alone, the cardiology community listens closely.

---

[THE DISCOVERY]

A meta-analysis published in the International Journal of Cardiology pooled data from four randomized controlled trials — 1,446 patients total — comparing IVUS-guided percutaneous coronary intervention (PCI) to standard angiography-guided PCI in patients with unprotected left main coronary artery disease. The headline result: major adverse cardiovascular events (MACE) showed a trend favoring IVUS guidance, but the difference didn't reach statistical significance. The risk ratio was 0.57 — suggesting a 43% relative reduction in MACE with IVUS — but the confidence interval (0.30 to 1.09) crossed 1, and the p-value landed at 0.09.

---

[THE SCIENCE BEHIND IT]

IVUS — intravascular ultrasound — gives the interventional cardiologist a real-time cross-sectional image of the artery from the inside, rather than relying on the silhouette of contrast dye in an X-ray. In theory, it allows for more precise stent sizing, better stent apposition, and earlier detection of complications. For routine coronary stenting, IVUS guidance has already demonstrated benefit in larger trials. Left main disease is the high-stakes frontier where that evidence had been thinner.

This meta-analysis took the most rigorous approach available by pooling RCT data. But four trials with a combined 1,446 patients, when the primary endpoint is MACE, is almost certainly underpowered — a finding this close to significance (p=0.09) with a large-magnitude effect estimate almost certainly means more data would tip it to significance. The main methodological concern is that MACE rates and follow-up durations almost certainly varied across trials, contributing to uncertainty in the pooled estimate.

The key limitation is insufficient statistical power, not absence of effect.

---

[WHO THIS HELPS]

Patients with unprotected left main coronary artery disease undergoing PCI — a high-risk group that includes many older adults with multivessel disease who may not be surgical candidates for bypass grafting. This is not a small population: coronary artery disease is the world's leading cause of death, and left main involvement affects a meaningful subset of the most critically ill cardiac patients.

---

[THE REAL-WORLD IMPACT]

IVUS equipment is already available in most advanced cardiac catheterization laboratories in high-income countries. If future trials or a larger pooled analysis confirm the trend to statistical significance, guidelines could shift from recommending IVUS "consider" to "should use" in left main PCI — influencing thousands of procedures annually. In the current landscape, this meta-analysis provides ammunition for operators who already use IVUS routinely, and cautionary nuance for those who don't. The result does not support abandoning IVUS based on a null p-value when the effect estimate is this large and confidence intervals are this wide.

---

[WHAT WE STILL DON'T KNOW]

The primary question — does IVUS-guided PCI meaningfully reduce MACE in left main disease — remains statistically unresolved. We need either larger trials with pre-specified MACE endpoints or a larger meta-analysis as more trial data accrue. We also don't know whether benefit varies by left main anatomy (ostial vs. distal vs. bifurcation), stent type, or adjunct pharmacotherapy. Cost-effectiveness analysis is absent.

---

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate — the trend is consistent and the effect estimate is large; statistical significance is likely a power problem, not a true null
• Translation Speed: 2–5 years, pending additional trial data or updated guideline review
• Barrier Analysis:
  • Regulatory: IVUS is already approved and available; no regulatory hurdle
  • Reimbursement: IVUS adds procedural cost; payer coverage varies; may discourage use in cost-sensitive environments
  • Infrastructure: IVUS requires equipment and operator training; significant gap between high- and low-resource cardiac centers
  • Equity: Access to IVUS-capable cath labs skews toward academic and urban hospitals; rural and underserved patients may not benefit

---

[CALL TO ACTION / CLOSING]

A 43% relative reduction in major cardiac events is a signal too large to dismiss — even when the p-value doesn't quite cross the threshold. This meta-analysis makes a compelling case for powering a definitive trial in left main PCI, and in the meantime, operators with IVUS access have good reason to use it.

---

---

[HOOK]

Immunotherapy has transformed cancer care for hundreds of thousands of patients with melanoma — but it comes with a trade-off. When you turbocharge the immune system to attack cancer, it sometimes attacks healthy tissue too. Skin reactions — rashes, dermatitis, sometimes severe — affect a large portion of patients on immune checkpoint inhibitors. Right now, there's no way to know in advance who's most at risk. A new study asks: could the answer be written in your DNA?

---

[THE DISCOVERY]

Researchers analyzed data from 744 melanoma patients treated with immune checkpoint inhibitors across multiple clinical trials and identified two genetic variants — single nucleotide polymorphisms, or SNPs — associated with the risk and severity of immunotherapy-related dermatitis. They combined these two SNPs into a polygenic risk score, and that score showed modest ability to predict which patients would develop skin side effects. The discrimination metric — the area under the receiver operating characteristic curve, or AUC — came in at 0.63.

---

[THE SCIENCE BEHIND IT]

The study is a cohort analysis within a well-characterized melanoma clinical trial population — a rigorous starting point for biomarker discovery. The authors used genome-wide or targeted genotyping to identify SNPs, then built a two-SNP polygenic risk score. The study is published in Melanoma Research with high classification confidence and a sample size of 744, which is reasonable for this type of discovery work.

The critical limitation — and it's an important one — is that this is a derivation cohort only. There is no external validation in an independent patient population. An AUC of 0.63 is real discrimination, but it's well below the clinical threshold generally needed for actionable risk stratification (typically 0.75 or higher). This is a promising discovery that needs replication and refinement.

A second concern: GWAS-derived SNPs perform substantially worse in non-European ancestries because the reference populations from which they're derived are predominantly European. Melanoma is already more common in fair-skinned populations, but as checkpoint inhibitors expand across cancer types, a Eurocentric PRS could underserve exactly the patients who most need accurate toxicity prediction.

---

[WHO THIS HELPS]

Melanoma patients receiving immune checkpoint inhibitors — including anti-CTLA-4 (ipilimumab), anti-PD-1 (nivolumab, pembrolizumab), and combination regimens. In the US, approximately 100,000 patients receive ICIs annually across melanoma and other cancer types; the broader ICI market encompasses lung cancer, kidney cancer, bladder cancer, and more. If a validated PRS were developed, dermatologists and oncologists could use it pre-treatment to counsel patients, intensify skin monitoring protocols, or in severe-risk cases, prepare prophylactic management strategies.

---

[THE REAL-WORLD IMPACT]

The immediate clinical impact is limited by the modest AUC and absence of external validation. If this two-SNP PRS were validated and refined — particularly with larger, more diverse cohorts and additional SNPs incorporated — it could eventually feed into pre-treatment genetic screening panels for patients starting ICI therapy. The workflow implications are modest: germline genotyping is increasingly routine and low-cost. The barrier is performance, not implementation.

For now, the most meaningful real-world impact is scientific: this study opens a line of investigation into genetic determinants of ICI toxicity that could ultimately enable personalized immune monitoring protocols.

---

[WHAT WE STILL DON'T KNOW]

Whether this two-SNP PRS replicates in independent cohorts is the central unanswered question. We also don't know whether the SNPs identified have known biological functions relevant to immune regulation of the skin, what the sensitivity and specificity are at clinically useful cutpoints, or whether adding more SNPs (a larger PRS) would improve discrimination to actionable levels. And critically — how does this PRS perform in Black, Asian, and Hispanic melanoma patients?

---

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Low-Moderate — discovery is credible; clinical utility unproven
• Translation Speed: 5–10 years to potential clinical application, contingent on multi-cohort replication and performance improvement
• Barrier Analysis:
  • Regulatory: A companion diagnostic application would require FDA/CE clearance
  • Reimbursement: Germline SNP testing for toxicity prediction is not currently reimbursed; payer case needs to be built
  • Cost: Low — SNP genotyping is inexpensive; integration into existing pre-treatment panels is feasible
  • Equity: Current PRS likely underperforms in non-European populations — a known and serious limitation of GWAS-based tools that the field must address proactively
  • Awareness: Oncologists are not yet trained to interpret germline toxicity PRS scores; clinician education would be needed

---

[CALL TO ACTION / CLOSING]

The idea that your genetic blueprint could tell your oncologist whether immunotherapy will cause a skin reaction before you ever take the first dose is compelling — and now there's early evidence it might be possible. The next step is replication in diverse, independent cohorts, because a PRS that only works for some patients isn't the tool the field needs.